{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:53:30Z","timestamp":1790931210222,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The objective of this study was to investigate the clinical and imaging features of tepotinib\u2010induced interstitial lung disease (ILD) using real\u2010world data obtained during routine clinical use of tepotinib in Japan. The study was conducted as a voluntary safety\u2010monitoring activity and targeted cases reported during the period from 1st June 2020 (the launch date of tepotinib in Japan) to 31st December 2023. An ILD adjudication committee, composed of external respiratory and radiology experts, assessed the clinical and imaging features of the ILD. The committee expertly identified 35 patients with tepotinib\u2010induced ILD, with an estimated reported incidence of 2.9% (35\/1190 patients). The estimated reported incidence of the fatal ILD was 0.9% (11\/1190 patients). More than half of the ILDs were classified as \u2264grade 2 (19\/35 patients), with the predominant imaging pattern of organizing pneumonia (OP) (15\/19 patients), followed by hypersensitivity pneumonitis (HP) and diffuse alveolar damage (DAD) patterns (3 and 1\/19 patients, respectively). In contrast, among the \u2265grade 3 ILDs (15\/35 patients), DAD was the most frequently observed pattern (7\/15 patients), followed by OP and HP patterns (6 and 2\/15 patients, respectively). The median time to onset of the 35 ILDs from the start of tepotinib administration was 50.0\u2009days (range: 4\u2013205\u2009days). Fatal outcomes occurred more frequently in patients with pre\u2010existing ILD\/interstitial lung abnormality (ILA) (8\/12 patients), whereas most patients without pre\u2010existing ILD\/ILA experienced better outcomes of recovered\/resolving (19\/23 patients). These findings highlight the importance of close monitoring for ILD occurrence during the real\u2010world clinical use of tepotinib.<\/jats:p>","DOI":"10.1111\/cas.70471","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:54:11Z","timestamp":1784091251000},"page":"2827-2837","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical and Imaging Features of Tepotinib\u2010Induced Interstitial Lung Disease in the Post\u2010Marketing Setting in Japan"],"prefix":"10.1111","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-1424","authenticated-orcid":false,"given":"Terufumi","family":"Kato","sequence":"first","affiliation":[{"name":"Clinical Research and Trial Center Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Baba","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Kanagawa Cardiovascular and Respiratory Center  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Endo","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Radiology Shizuoka Cancer Center  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehla","family":"Endo","sequence":"additional","affiliation":[{"name":"Global Patient Safety Japan Merck Biopharma Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Horii","sequence":"additional","affiliation":[{"name":"Oncology Medical Affairs Merck Biopharma Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34757"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(15)01125\u20103"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.11.011"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004407"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.1962"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyab072"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16107"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010020\u201001317\u20109"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21184"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010016\u20100450\u20109"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25154"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3012"},{"key":"e_1_2_13_14_1","unstructured":"Merck Biopharma Co. Ltd. Proper Use Guide of TEPMETKO Tablets 250\u2009mg https:\/\/www.hcpmrkjp.com\/wp\u2010content\/uploads\/product\/tpl_pug.pdf."},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaf099"},{"key":"e_1_2_13_16_1","volume-title":"Cancer Therapy Evaluation Program","author":"National Cancer Institute","year":"2017"},{"key":"e_1_2_13_17_1","volume-title":"The JRS Guidelines for the Management of Drug\u2010Induced Lung Disease","author":"The Japanese Respiratory Society","year":"2018"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147\u2010023\u201002414\u2010x"},{"key":"e_1_2_13_19_1","unstructured":"Merck Biopharma Co. Ltd. Package Insert for TEPMETKO Tablets 250\u2009mg https:\/\/hcp.merckgroup.com\/content\/dam\/web\/healthcare\/medinfo\/documents\/tepmetko\/tepmetko_insert_202005_JP.pdf."},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620938595"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201021\u20102733"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200710\u20101501OC"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12550"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy179"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.05.035"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1361443"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.11.022"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020\u20100760"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.06.008"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002787"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101952"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4526"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.08.025"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14710"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000543251"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.70471","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cas.70471","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.70471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:05:58Z","timestamp":1790928358000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.70471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/cas.70471"],"URL":"https:\/\/doi.org\/10.1111\/cas.70471","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"2026-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}